ML
DFTX

McAdam LLC’s Definium Therapeutics DFTX Stock Holding History

McAdam LLC’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
+6,879
New +$170K 0.01% 366

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

McAdam LLC's DFTX Position: Q2 2026 in Review

McAdam LLC opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 6,879 shares worth $324K. The stake represents 0.01% of the portfolio and ranks #366 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • McAdam LLC held 6,879 shares of Definium Therapeutics worth $324K as of Q2 2026.
  • Definium Therapeutics was a new McAdam LLC position in Q2 2026.
  • Definium Therapeutics made up 0.01% of McAdam LLC's portfolio in Q2 2026, its #366 holding.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on McAdam LLC's 13F filing for Q2 2026, filed 4 Aug 2026.